UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 81 ...

Financial Performance - The company reported a net loss of approximately $2.2 million for the three months ended March 31, 2025, compared to a net loss of $6.5 million for the same period in 2024, representing a decrease of $4.3 million[87]. - The company has accumulated deficits of approximately $84.2 million as of March 31, 2025, indicating ongoing financial challenges[78]. - The company has incurred recurring losses and needs to raise additional funds to sustain operations, raising substantial doubt about its ability to continue as a going concern[77]. Expenses - Research and development expenses increased by approximately $293,000 (65%) during the three months ended March 31, 2025, driven by increased chemistry, manufacturing, and controls expenses[88]. - General and administrative expenses rose by approximately $129,000 (9%) during the same period, primarily due to higher compensation and consulting costs[89]. Cash and Financing - The company had cash and cash equivalents of $2.4 million as of March 31, 2025, which increased to approximately $3.9 million by May 12, 2025[97]. - The company received net proceeds of approximately $2.35 million from a warrant inducement agreement that closed on May 5, 2025, to support working capital[84]. - The company expects to require $8-12 million for each of the two additional Phase 3 trials for AD04, along with up to $5 million in other development expenses[98]. - The company has no committed sources of funding and is restricted by SEC and Nasdaq rules regarding its ATM Agreement and equity line[99]. - The company is actively pursuing financing and other strategic plans but cannot assure that such financing will be available on acceptable terms[99]. Cash Flow - Net cash used in operating activities decreased by approximately $41,000, from $1,626,000 in Q1 2024 to $1,585,000 in Q1 2025[102]. - Net cash provided by investing activities increased by approximately $150,000 due to a milestone payment received from Adovate[103]. - Net cash provided by financing activities decreased by approximately $3,774,000, from $3,824,000 in Q1 2024 to $51,000 in Q1 2025[104]. - The company reported a net increase in cash and cash equivalents of $(1,384,000) in Q1 2025 compared to an increase of $2,198,000 in Q1 2024[101]. Research and Development - The company plans to begin a Phase III study of AD04 in the second half of 2025, with a contract signed for approximately $2.3 million to produce sufficient drug product for the study[97]. - The FDA has accepted a new in-vitro bridging strategy for AD04, allowing for heavy-drinking-day based endpoints for approval instead of abstinence-based endpoints[82]. - Without additional funding, the company may need to delay, scale back, or eliminate some or all of its research and development programs[99]. Accounting and Estimates - The company does not have any off-balance sheet arrangements[105]. - The company has not identified any critical accounting estimates that could materially affect its financial condition[107].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36210 LiqTech International, Inc. (Exact name of registrant as specified in its charter) Nevada 20-1431677 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 GLOBAL GAS CORPORATION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-39819 (Exact name of registrant as specified in its charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-39819 GLOBAL GAS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42368 RISING DRAGON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42368 RISING DRAGON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

Financial Performance - Research & Development Revenue for FY 2024 was $29.6 million, a 63.5% increase from $18.1 million in FY 2023[12] - The net loss for FY 2024 was $(15.3) million, or $(0.85) per share, compared to a net loss of $(20.9) million, or $(1.48) per share, for FY 2023[17] - Gross profit for the year ended December 31, 2024, was $13,274,000, up 68% from $7,880,000 in 2023[31] - Operating loss decreased to $6,582,000 for the year ended December 31, 2024, compared to $12,984,000 in 2023, indicating improved operational efficiency[31] - Net loss for the year ended December 31, 2024, was $15,315,000, a reduction from $20,854,000 in 2023, reflecting a 27% improvement[31] - Basic and diluted net loss per share for 2024 was $0.85, down from $1.48 in 2023, showing a significant reduction in loss per share[31] - Total comprehensive loss for the year ended December 31, 2024, was $15,324,000, compared to $20,842,000 in 2023, reflecting a 27% decrease[31] - Cash used in operating activities for the year ended December 31, 2024, was $9,198,000, an improvement from $13,240,000 in 2023[33] - Net cash provided by financing activities in 2024 was $9,575,000, compared to $3,844,000 in 2023, indicating increased financing support[33] - The company ended 2024 with cash of $5,157,000, up from $4,790,000 at the beginning of the year[33] Revenue Projections - The Company expects to realize its first commercial product revenue in the second half of 2025, with a forecasted revenue of approximately $21.5 million for FY 2025[19] Research and Development - The Company has a multi-year, non-dilutive BARDA PBS contract valued at up to $150 million, with an initial award of approximately $54.9 million[4] - Research and development revenue for Q4 2024 was $7,604,000, a 44% increase from $5,287,000 in Q4 2023[31] - The Burn Validation Study involved 160 patients at 14 burn centers across the US, making it one of the largest burn studies conducted[9] - The Company plans to submit regulatory filings for the DeepView System for burns in the first half of 2025[3] Product Performance - The DeepView System achieved an image-wise sensitivity score of 86.6%, significantly outperforming burn physicians' clinical judgment annotation score of 40.8%[5] Contractual Agreements - The Company completed an equity financing and long-term debt transaction, raising $11.2 million to support its objectives[16] Margins - The gross margin for FY 2024 rose to 44.9% from 43.6%, reflecting the expansion of work under the BARDA PBS contract[13] Cash Position - As of December 31, 2024, cash was $5.2 million, with total current assets amounting to $10.1 million[29]

(MARK ONE) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42414 Dynamix Corporation (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 00-0000000 (State or other jurisdiction of ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-42414 (MARK ONE) FORM 10-Q (I.R.S. Employer Identification No.) 1980 Post Oak Blvd., Suite 100 PMB 6373 Houston, TX, 77056 (Address of principal executive offic ...